Adamis Pharmaceuticl (ADMP) 6.50 $ADMP
Adamis Pharmaceuticals Receives Notice of Allowance for US and Japanese Patents for Its Dry Powder Inhaler
GlobeNewswire - Wed Jan 28, 9:28AM CST
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company"
recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No. 13/320,762) and in Japan (Japanese Patent Application No. 2012-511965). The approved claims describe the device and components that are important for its function.
ADMP: 6.50 (-0.01)
Adamis Pharmaceuticals: A Specialty Pharma Ready For The Next Level
James W. Burke - Seeking Alpha - Wed Jan 21, 9:54AM CST
It was just over a year ago that I wrote an article on a small, relatively unknown company, Adamis Pharmaceuticals (NASDAQ: ADMP ). In the article, I explained how Adamis was really two great companies for the price of one: the Specialty...
SLXP: 152.35 (+3.17), ADMP: 6.50 (-0.01), MYL: 55.85 (+1.34)
Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
M2 - Wed Jan 21, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/qxt9lq/global_prostate) has announced the addition of the "Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015" report to their offering. Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical care. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years. Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients. Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015 Report Highlights: - Introduction to Prostate Cancer Vaccine - Mechanism of Prostate Cancer Vaccine - Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase - Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines - Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines - Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation) Key Topics Covered: 1. Introduction to Prostate Cancer Vaccine 2. Mechanism of Prostate Cancer Vaccine 3. Global Prostate Cancer Vaccine Market Dynamics 4. Global Prostate Cancer Vaccine Market Outlook 5. Global Prostate Cancer Vaccine Market Future Prospects 6. Personalized Cancer Vaccine Market Opportunities 7. Global Prostate Cancer Vaccines Clinical Trial Insight by Company, Country & Phase 8. Marketed Prostate Cancer Vaccines by Company & Country 9. Suspended & Discontinued Prostate Cancer Vaccines in Clinical Trials 10. Competitive Landscape - Adamis Pharmaceuticals - Aduro BioTech - Bellicum Pharmaceuticals - CytoVac - Dendreon Corporation - Generex Biotechnology Corporation - Immunovaccine - Oncbiomune - Progenics - Sotio For more information visit http://www.researchandmarkets.com/research/qx...l_prostate
BLCM: 20.00 (-0.81), ADMP: 6.50 (-0.01)
Adamis Pharmaceuticals concludes public offering at USD5.00 per share
M2 - Thu Jan 15, 5:08AM CST
Biopharmaceutical company Adamis Pharmaceuticals (NasdaqCM:ADMP) said on Wednesday that it has completed its public offering of 2,000,000 shares of common stock at USD5.00 per share.
ADMP: 6.50 (-0.01)
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
GlobeNewswire - Wed Jan 14, 9:20AM CST
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today the closing of its previously announced underwritten public offering of 2,000,000 shares of common stock at a public offering price of $5.00 per share, as well as 300,000 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters.
ADMP: 6.50 (-0.01)
Direction of Market Influences: New Coverage of Acorda, Acura Pharmaceuticals, Adamas, Adamis and Addus HomeCare
PR Newswire - Wed Jan 14, 6:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Acorda (NASDAQ: ACOR), Acura Pharmaceuticals (NASDAQ: ACUR), Adamas (NASDAQ: ADMS), Adamis (NASDAQ: ADMP), and Addus HomeCare (NASDAQ: ADUS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ADMS: 16.98 (+0.03), ADUS: 21.57 (+0.18), ADMP: 6.50 (-0.01), ACOR: 36.14 (-0.51), ACUR: 0.55 (+0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 11:47AM CST
EOPN: 8.55 (-0.01), ADHD: 6.92 (+0.73), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), FIVE: 33.01 (+0.11), TESO: 11.37 (+0.37), ALXA: 2.07 (+0.09), PRTO: 10.45 (unch), AGEN: 5.03 (-0.01), ARGS: 8.35 (-0.12), TOPS: 1.14 (+0.02), HILL: 4.42 (+0.06), EDAP: 3.55 (+0.13), CTSO: 8.20 (+0.18), VLCCF: 4.15 (-0.06), SCYX: 9.48 (+0.07), VIMC: 8.59 (-0.08), SBLK: 4.48 (+0.15), DCTH: 1.14 (+0.04), IDN: 1.43 (-0.01)
Adamis plummets after pricing offering at a discount
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 9:32AM CST
ADMP: 6.50 (-0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 8:10AM CST
SD: 2.09 (+0.14), PTLA: 34.96 (+3.13), EOPN: 8.55 (-0.01), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), INFY: 36.60 (-0.13), FIVE: 33.01 (+0.11), AGEN: 5.03 (-0.01), SAN: 7.18 (+0.13), EDAP: 3.55 (+0.13), GMLP: 28.17 (+0.45), CTSO: 8.20 (+0.18), SBLK: 4.48 (+0.15), IDN: 1.43 (-0.01)
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Fri Jan 09, 8:04AM CST
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today the pricing of its previously announced underwritten public offering of 2,000,000 shares of common stock at a public offering price of $5.00 per share, resulting in gross proceeds of approximately $10,000,000.
ADMP: 6.50 (-0.01)
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Jan 08, 3:36PM CST
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today that it intends to offer shares of its common stock in an underwritten public offering. The company expects to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ADMP: 6.50 (-0.01)
Adamis Pharmaceuticals to Present at Two Upcoming Conferences
GlobeNewswire - Tue Dec 02, 8:01AM CST
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced that the Company is scheduled to present a company overview at two upcoming conferences.
ADMP: 6.50 (-0.01)
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/53cpct/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 100 companies are cited in this text including: - Ache Laboratorios Farmaceuticos S/A - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - AIM Therapeutics Inc. - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Daiichi Sankyo Company, Limited - Errant Gene Therapeutics, LLC - Five Prime Therapeutics, Inc. - GlaxoSmithKline plc - Hydra Biosciences, Inc. - iCeutica, Inc. - Johnson & Johnson - KaloBios Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Novartis AG - Ockham Biotech Limited - Pfizer Inc. - PharmaLundensis - Re-Pharm - Seoul Pharma - Takeda Pharmaceutical Company - Zambon Company For more information visit http://www.researchandmarkets.com/research/53cpct/chronic
JNJ: 99.62 (+1.18), KBIO: 0.45 (+0.06), PFE: 34.64 (-0.23), ADMP: 6.50 (-0.01), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17), FPRX: 24.63 (+0.63)
Contraception - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/rzn2sh/contraception) has announced the addition of the "Contraception - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Contraception - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actavis - Adamis Pharmaceuticals - Agile - ANI - Antares - Bayer - Evofem - HRA Pharma - Hydra Biosciences - Intas - Ligand - Merck & Co - Orbis Biosciences - Pantarhei Bioscience - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/rz...traception
MRK: 58.81 (-0.07), ADMP: 6.50 (-0.01), TEVA: 56.77 (-0.58)
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 25.34 (+1.20), CMRX: 40.16 (+0.08), CVM: 0.84 (-0.01), ADMP: 6.50 (-0.01), GNCA: 8.93 (-0.07)
Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams
GlobeNewswire - Wed Oct 15, 8:35AM CDT
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its medical and product marketing management teams. These new employees position the company for further development of its product pipeline and the preparation of a sales and marketing plan for the anticipated launch of its epinephrine pre-filled syringe for treatment of allergic reactions (Type I) including anaphylaxis.
ADMP: 6.50 (-0.01)
Market Maker Surveillance Report. IDN, VII, ISNS, DGLY, MGT, ADMP, Winning Stocks With Lowest Price Friction For Tuesday, September 2nd 2014
M2 - Thu Sep 04, 9:47AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4916 companies with "abnormal" market making, 2511 companies with positive Friction Factors and 2570 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Intellicheck Mobilisa Inc (NYSE:IDN), Vicon Industries Inc (NYSE:VII), Image Sensing Systems Inc (NASDAQ:ISNS), Digital Ally Inc (NASDAQ
GLY), MGT Capital Investments Inc (NYSE:MGT), Adamis Pharmaceuticals Corp (NASDAQ:ADMP). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
MGT: 0.53 (+0.04), ADMP: 6.50 (-0.01), ISNS: 2.49 (+0.03), VII: 1.47 (-0.02), DGLY: 11.50 (-0.40), IDN: 1.43 (-0.01)
Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors
Marketwire - Tue Aug 26, 6:15AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board.
ADMP: 6.50 (-0.01)
Adamis Pharmaceuticals raises USD5m from private placement of convertible preferred stock
M2 - Wed Aug 20, 9:24AM CDT
Biopharmaceutical company Adamis Pharmaceuticals (NASDAQ:ADMP) revealed on Tuesday the issuance of 1,418,439 shares of Series A convertible preferred stock to a fundamental healthcare institutional fund for gross cash proceeds of about USD5m in a private placement.
ADMP: 6.50 (-0.01)
Adamis Pharmaceuticals Receives Notice of Allowance for US and Japanese Patents for Its Dry Powder Inhaler
GlobeNewswire - Wed Jan 28, 9:28AM CST
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) ("Company"
recently received a notice of allowance that one of its patent applications for its proprietary dry powder inhaler, Taper DPI, will issue in the United States (U.S. Patent Application No. 13/320,762) and in Japan (Japanese Patent Application No. 2012-511965). The approved claims describe the device and components that are important for its function. ADMP: 6.50 (-0.01)
Adamis Pharmaceuticals: A Specialty Pharma Ready For The Next Level
James W. Burke - Seeking Alpha - Wed Jan 21, 9:54AM CST
It was just over a year ago that I wrote an article on a small, relatively unknown company, Adamis Pharmaceuticals (NASDAQ: ADMP ). In the article, I explained how Adamis was really two great companies for the price of one: the Specialty...
SLXP: 152.35 (+3.17), ADMP: 6.50 (-0.01), MYL: 55.85 (+1.34)
Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
M2 - Wed Jan 21, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/qxt9lq/global_prostate) has announced the addition of the "Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015" report to their offering. Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical care. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years. Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients. Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015 Report Highlights: - Introduction to Prostate Cancer Vaccine - Mechanism of Prostate Cancer Vaccine - Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase - Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines - Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines - Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation) Key Topics Covered: 1. Introduction to Prostate Cancer Vaccine 2. Mechanism of Prostate Cancer Vaccine 3. Global Prostate Cancer Vaccine Market Dynamics 4. Global Prostate Cancer Vaccine Market Outlook 5. Global Prostate Cancer Vaccine Market Future Prospects 6. Personalized Cancer Vaccine Market Opportunities 7. Global Prostate Cancer Vaccines Clinical Trial Insight by Company, Country & Phase 8. Marketed Prostate Cancer Vaccines by Company & Country 9. Suspended & Discontinued Prostate Cancer Vaccines in Clinical Trials 10. Competitive Landscape - Adamis Pharmaceuticals - Aduro BioTech - Bellicum Pharmaceuticals - CytoVac - Dendreon Corporation - Generex Biotechnology Corporation - Immunovaccine - Oncbiomune - Progenics - Sotio For more information visit http://www.researchandmarkets.com/research/qx...l_prostate
BLCM: 20.00 (-0.81), ADMP: 6.50 (-0.01)
Adamis Pharmaceuticals concludes public offering at USD5.00 per share
M2 - Thu Jan 15, 5:08AM CST
Biopharmaceutical company Adamis Pharmaceuticals (NasdaqCM:ADMP) said on Wednesday that it has completed its public offering of 2,000,000 shares of common stock at USD5.00 per share.
ADMP: 6.50 (-0.01)
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
GlobeNewswire - Wed Jan 14, 9:20AM CST
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today the closing of its previously announced underwritten public offering of 2,000,000 shares of common stock at a public offering price of $5.00 per share, as well as 300,000 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters.
ADMP: 6.50 (-0.01)
Direction of Market Influences: New Coverage of Acorda, Acura Pharmaceuticals, Adamas, Adamis and Addus HomeCare
PR Newswire - Wed Jan 14, 6:30AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Acorda (NASDAQ: ACOR), Acura Pharmaceuticals (NASDAQ: ACUR), Adamas (NASDAQ: ADMS), Adamis (NASDAQ: ADMP), and Addus HomeCare (NASDAQ: ADUS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ADMS: 16.98 (+0.03), ADUS: 21.57 (+0.18), ADMP: 6.50 (-0.01), ACOR: 36.14 (-0.51), ACUR: 0.55 (+0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 11:47AM CST
EOPN: 8.55 (-0.01), ADHD: 6.92 (+0.73), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), FIVE: 33.01 (+0.11), TESO: 11.37 (+0.37), ALXA: 2.07 (+0.09), PRTO: 10.45 (unch), AGEN: 5.03 (-0.01), ARGS: 8.35 (-0.12), TOPS: 1.14 (+0.02), HILL: 4.42 (+0.06), EDAP: 3.55 (+0.13), CTSO: 8.20 (+0.18), VLCCF: 4.15 (-0.06), SCYX: 9.48 (+0.07), VIMC: 8.59 (-0.08), SBLK: 4.48 (+0.15), DCTH: 1.14 (+0.04), IDN: 1.43 (-0.01)
Adamis plummets after pricing offering at a discount
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 9:32AM CST
ADMP: 6.50 (-0.01)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 8:10AM CST
SD: 2.09 (+0.14), PTLA: 34.96 (+3.13), EOPN: 8.55 (-0.01), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), INFY: 36.60 (-0.13), FIVE: 33.01 (+0.11), AGEN: 5.03 (-0.01), SAN: 7.18 (+0.13), EDAP: 3.55 (+0.13), GMLP: 28.17 (+0.45), CTSO: 8.20 (+0.18), SBLK: 4.48 (+0.15), IDN: 1.43 (-0.01)
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Fri Jan 09, 8:04AM CST
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today the pricing of its previously announced underwritten public offering of 2,000,000 shares of common stock at a public offering price of $5.00 per share, resulting in gross proceeds of approximately $10,000,000.
ADMP: 6.50 (-0.01)
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Thu Jan 08, 3:36PM CST
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, announced today that it intends to offer shares of its common stock in an underwritten public offering. The company expects to grant the underwriters of the offering an option to purchase additional shares of common stock to cover over-allotments, if any. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
ADMP: 6.50 (-0.01)
Adamis Pharmaceuticals to Present at Two Upcoming Conferences
GlobeNewswire - Tue Dec 02, 8:01AM CST
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced that the Company is scheduled to present a company overview at two upcoming conferences.
ADMP: 6.50 (-0.01)
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/53cpct/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 100 companies are cited in this text including: - Ache Laboratorios Farmaceuticos S/A - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - AIM Therapeutics Inc. - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Daiichi Sankyo Company, Limited - Errant Gene Therapeutics, LLC - Five Prime Therapeutics, Inc. - GlaxoSmithKline plc - Hydra Biosciences, Inc. - iCeutica, Inc. - Johnson & Johnson - KaloBios Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Novartis AG - Ockham Biotech Limited - Pfizer Inc. - PharmaLundensis - Re-Pharm - Seoul Pharma - Takeda Pharmaceutical Company - Zambon Company For more information visit http://www.researchandmarkets.com/research/53cpct/chronic
JNJ: 99.62 (+1.18), KBIO: 0.45 (+0.06), PFE: 34.64 (-0.23), ADMP: 6.50 (-0.01), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17), FPRX: 24.63 (+0.63)
Contraception - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/rzn2sh/contraception) has announced the addition of the "Contraception - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Contraception - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actavis - Adamis Pharmaceuticals - Agile - ANI - Antares - Bayer - Evofem - HRA Pharma - Hydra Biosciences - Intas - Ligand - Merck & Co - Orbis Biosciences - Pantarhei Bioscience - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/rz...traception
MRK: 58.81 (-0.07), ADMP: 6.50 (-0.01), TEVA: 56.77 (-0.58)
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 25.34 (+1.20), CMRX: 40.16 (+0.08), CVM: 0.84 (-0.01), ADMP: 6.50 (-0.01), GNCA: 8.93 (-0.07)
Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams
GlobeNewswire - Wed Oct 15, 8:35AM CDT
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its medical and product marketing management teams. These new employees position the company for further development of its product pipeline and the preparation of a sales and marketing plan for the anticipated launch of its epinephrine pre-filled syringe for treatment of allergic reactions (Type I) including anaphylaxis.
ADMP: 6.50 (-0.01)
Market Maker Surveillance Report. IDN, VII, ISNS, DGLY, MGT, ADMP, Winning Stocks With Lowest Price Friction For Tuesday, September 2nd 2014
M2 - Thu Sep 04, 9:47AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4916 companies with "abnormal" market making, 2511 companies with positive Friction Factors and 2570 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Intellicheck Mobilisa Inc (NYSE:IDN), Vicon Industries Inc (NYSE:VII), Image Sensing Systems Inc (NASDAQ:ISNS), Digital Ally Inc (NASDAQ
GLY), MGT Capital Investments Inc (NYSE:MGT), Adamis Pharmaceuticals Corp (NASDAQ:ADMP). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net . MGT: 0.53 (+0.04), ADMP: 6.50 (-0.01), ISNS: 2.49 (+0.03), VII: 1.47 (-0.02), DGLY: 11.50 (-0.40), IDN: 1.43 (-0.01)
Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors
Marketwire - Tue Aug 26, 6:15AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board.
ADMP: 6.50 (-0.01)
Adamis Pharmaceuticals raises USD5m from private placement of convertible preferred stock
M2 - Wed Aug 20, 9:24AM CDT
Biopharmaceutical company Adamis Pharmaceuticals (NASDAQ:ADMP) revealed on Tuesday the issuance of 1,418,439 shares of Series A convertible preferred stock to a fundamental healthcare institutional fund for gross cash proceeds of about USD5m in a private placement.
ADMP: 6.50 (-0.01)
